In India, copycat competition closes in on Avastin
The Indian subsidiary of Netherlands-incorporated Mylan (Nasdaq: MYL) has launched Abevmy (bevacizumab), its biosimilar version of Roche’s (ROG: SIX) Avastin.
The monoclonal antibody has been approved by India’s medicines regulator for all indications of the reference product, including for the treatment of colorectal, lung, ovarian, cervical and other cancers.
The launch comes just days after local biotech firm Biocon (BSE: 532523) started retailing its Avastin copycat Krabeva in the country at a price of 24,000 rupees ($369) for a 100mg vial, undercutting Roche’s 29,500 rupee price tag.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze